Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Breast Cancer Clinical Trials
A listing of Breast Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Anniston : Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bessemer : Alabama Oncology Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Birmingham : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Birmingham : University Of Alabama at Birmingham Updated
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
View More »
Birmingham :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Birmingham : Universito of Birmingham atAlabama
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Birmingham :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Birmingham : University of Alabama - Birmingham
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Birmingham : University of Alabama at Birmingham
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Birmingham : Bruno Cancer Center
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Birmingham :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Birmingham : Site Reference ID/Investigator# 62994
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Mobile : University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2)
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Mobile : Providence Cancer Center at Providence Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Muscle Shoals : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Alaska
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Anchorage : Providence Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fairbanks : Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Arizona
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Chandler :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Chandler : Ironwood Cancer and Research Centers Ironwood Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Chandler : Ironwood Cancer and Research Centers Ironwood
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Glendale : Arizona Center for Cancer Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
View More »
Phoenix : Arizona Oncology Associates Dept of Oncology Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Phoenix : Banner Health Updated
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Phoenix : Arizona Oncology Associates Dept of Oncology
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Scottsdale :
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Scottsdale :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Scottsdale : Scottsdale Medical Imaging, Limited (SMIL)
Collection of FUJIFILM's 3Dimensional Mammograms
Scottsdale : Mayo Clinic Arizona
Dose-escalation Study of Oral CX-4945
Scottsdale : 21 Century Oncology
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Scottsdale :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Scottsdale : Pinnacle Oncology Hematology
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Sedona :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Tucson :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Tucson : Arizona Oncology Associates
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Tucson : University of Arizona
Excision Followed by Radiofrequency Ablation for Breast Cancer
Tucson : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Arkansas
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
View More »
Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Hot Springs :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Hot Springs :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Jonesboro :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Jonesboro : Sandoz Investigational Site
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Jonesboro : NEA Medical Clinic - East Matthews
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Little Rock : University of Arkansas for Medical Sciences
Excision Followed by Radiofrequency Ablation for Breast Cancer
Little Rock : University of Arkansas For Medical Sciences
Percutaneous Removal and Margin Ablation for Breast Cancer
Little Rock : Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Little Rock : Site Reference ID/Investigator# 60750
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Springdale : The Center for Chest Care
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
California
Duarte : City of Hope Updated
64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women with Advanced HER2 Positive Invasive Breast Cancer
Duarte : City of Hope Updated
A Pilot Study of the Impact of a Single Dose of Zoledronic Acid on Biomarkers in Breast Cancer
Duarte : City of Hope Updated
Adjuvant Therapy in Older versus Younger Women with Breast Cancer: Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life
Duarte : City of Hope Updated
Administrative Supplement to Expand NCI-Supported Community Outreach Capacity through Community Health Educators (CHEs) of the National Outreach Network
Duarte : City of Hope Updated
Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients with Locally Advanced or Metastatic Stage IV Breast Cancer
Duarte : City of Hope Updated
ECOG E2108: A Randomized Phase III Trial of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Duarte : City of Hope Updated
Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older with Metastatic Breast Cancer
Duarte : City of Hope Updated
Evaluation of Breast Cancer Patterns and Outcomes of Care
Duarte : City of Hope Updated
Expression of P16INK4a As a Predictor of Myelosuppression in Patients with Breast Cancer
Duarte : City of Hope Updated
Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors
Duarte : City of Hope Updated
Genetic Epidemiology of Breast and Ovarian Cancers
Duarte : City of Hope Updated
Impact of Adjuvant Chemotherapy on Metabolic Syndrome Risk Factors in Breast Cancer Patients
Duarte : City of Hope Updated
Long Term Follow-Up After Breast Cancer
Duarte : City of Hope Updated
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Duarte : City of Hope Updated
Older Breast Cancer Patients: Risk for Cognitive Decline
Duarte : City of Hope Updated
Phase II Trial of Neoadjuvant Chemotherapy with Carboplatin and NAB-Paclitaxel in Patients with Locally Advanced and Inflammatory Triple Negative Breast Cancer
Duarte : City of Hope Updated
PHII-117, NCI #8822: Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients with Advanced Breast Cancer
Duarte : City of Hope Updated
PHII-96 NCI#8264: Phase II Trial of Single Agent ABT-888 with Post-Progression Therapy of ABT-888 in Combination with Carboplatin in Patients with Stage IV BRCA-Associated Breast Cancer
Duarte : City of Hope Updated
Pro Inflammatory Cytokines and Neurobehavioral Symptoms in Women with Breast Cancer
Duarte : City of Hope Updated
Reducing Extremity Lymphedema through Axillary Lymphatic Preservation Surgery
Duarte : City of Hope Updated
RTOG 1005: A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
Duarte : City of Hope Updated
Sister Survivor: Improving the Survivorship Care of African-American Women with Breast Cancer
Duarte : City of Hope Updated
SWOG S1007: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Duarte : City of Hope Updated
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older with HER2 Positive Locally Advanced or Metastatic Breast Cancer
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Arcadia : Shapiro & Stafford & Yee & Polanski Study Coordinator
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Bakersfield :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Beverly Hills : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Burbank :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Burbank :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Burbank : Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Campbell :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Castro Valley : Valley Medical Oncology Consultants - Castro Valley
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Castro Valley : East Bay Radiation Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Concord : Cancer Care Center at John Muir Health - Concord Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Corona : Sandoz Investigational Site
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Duarte : GenBasix Incorporated
Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters
Duarte : City of Hope Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Duarte : City of Hope National Medical Center COH 3
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Encinitas :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Everett :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Fairfield : North Bay Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fountain Valley : Compassionate Cancer Care Medical Group CCCMG
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Fountain Valley : Research Site Updated
Video Impact on Neulasta Education
Fremont : Valley Medical Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fresno :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Fresno : Fresno Breast Surgery
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Fresno : Cancer Care Associates Dept.ofCancerCareAssoc.
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Fullerton : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Fullerton : St. Jude Medical Center, Virginia K. Crosson Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Fullerton : St. Jude Heritage Medical Group Virginia Crosson Cancer Center
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Grass Valley : Sierra Nevada Cancer Center at Sierra Nevada Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenbrae :
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Greenbrae :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Greenbrae : California Cancer Care Marian Speciality Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Greenbrae : Marin Cancer Center
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Hayward :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Hayward :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Irvine : Cancer Center of Irvine
Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-Risk" Breast Cancer Patients
La Jolla :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
La Jolla : University of California-San Diego - Rebecca and John Moores Cancer Center
Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System
La Jolla : University of California San Diego UCSD 3
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
La Jolla : University of California, San Diego
Quantitative Subharmonic Breast Imaging
La Jolla : Site Reference ID/Investigator# 60754
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
La Jolla : University of California San Diego SC-1
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
La Verne : Wilshire Oncology Medical Group
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Laguna Hills : South Orange County Surgical Medical Group Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Loma Linda : Loma Linda University Medical Center
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Long Beach : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Long Beach : Long Beach Memorial Medical Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Long Beach : BreastLink
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Long Beach : Coast Hematology Oncology Associates
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Long Beach : Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Los Angeles : Cedars Sinai Medical Center SC Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Los Angeles :
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Los Angeles : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Los Angeles :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Los Angeles :
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols
Los Angeles :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Los Angeles : Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Los Angeles : University of Southern California/Norris Cancer Hospital Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Los Angeles : Los Angeles Hematology/Oncology Medical Group LA Cancer Network
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Los Angeles : University of California at Los Angeles Dept. of UCLA
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Los Angeles : USC/Norris Comprehensive Cancer Center and Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Los Angeles :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Los Angeles : Site Reference ID/Investigator# 60760
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Los Angeles : Site Reference ID/Investigator# 60743
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Los Angeles : Cedars Sinai Medical Center Samuel Oschin Cancer Center
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Los Angeles : Cedars Sinai Medical Center
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Martinez : Contra Costa Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Marysville : Tibotec Therapeutics - Division of Ortho Biotech Products, LP
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Merced : Mercy Cancer Center at Mercy Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mission Hills : Research Site Updated
Video Impact on Neulasta Education
Monterey : Community Hospital of Monterey Peninsula
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Mountain View : El Camino Hospital Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newport Beach : Hoag Memorial Hospital Presbyterian
An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging
Oakland :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Oakland : Highland General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Bay Area Breast Surgeons, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : CCOP - Bay Area Tumor Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Larry G Strieff MD Medical Corporation
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Alta Bates Summit Medical Center - Summit Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Tom K Lee, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Epic Care - Oakland
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Orange : University of California, Irvine Medical Center
Patient Controlled Tissue Expansion for Breast Reconstruction
Orange : St. Joseph Hospital Regional Cancer Center - Orange
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oxnard : PMK Medical Group
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Oxnard : Ventura County Hematology and Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Oxnard : Ventura County Hematology and Oncology PMK Medical Group
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Palm Springs : Comprehensive Cancer Center - Palm Springs
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Pasadena : Huntington Memorial Hospital/Hill Breast Center
Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons
Pleasant Hill :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Pleasanton : Valley Medical Oncology Consultants - Pleasanton
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pomona : The Office of Dr. Swarna Chanduri, MD
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Rancho Cucamonga : Wilshire Oncology Medical Group
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Redondo Beach : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Roseville :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Roseville : Sutter Roseville Medical Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Roseville :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Sacramento :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Sacramento : Sutter Institute Updated
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Sacramento : UC Davis Medical Center
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Sacramento : Sutter Healthcare-Sacramento
Patient Controlled Tissue Expansion for Breast Reconstruction
Sacramento : University of California Davis Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sacramento :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Salinas : Pacific Cancer Care
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
San Diego :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
San Diego : Scripps Updated
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
San Diego : Moores UC San Diego Cancer Center (UCSD) Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
San Diego : Sharp Oncology (Comprehensive Breast Care of San Diego)
Excision Followed by Radiofrequency Ablation for Breast Cancer
San Diego : SHARP Memorial
NBRST: Prospective Neo-adjuvant REGISTRY Trial
San Diego : Kaiser Permanente-San Diego
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
San Francisco : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
San Francisco :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
San Francisco :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
San Francisco : University of California, San Francisco (UCSF), Hellen Diller Family Comprehensive Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
San Francisco : University of California, San Francisco
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
San Francisco : University of California San Francisco
Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
San Francisco : UCSF Helen Diller Family Comprehensive Cancer Center
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
San Francisco : University of California San Francisco
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
San Francisco :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
San Jose :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
San Jose : Good Samaritan Hospital, San Jose
Patient Controlled Tissue Expansion for Breast Reconstruction
San Jose :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
San Luis Obispo : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
San Luis Obispo : Coastal Integrative Cancer Care
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
San Pablo : Doctors Medical Center - San Pablo Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Santa Barbara : Sansum Clinic Updated
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Santa Barbara : Santa Barbara Hematolgy Oncology Medical Group
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Santa Clara :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Santa Clara :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Santa Maria : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Santa Maria : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Santa Maria : Central Coast Medical Oncology Corporation
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Santa Monica :
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols
Santa Monica : Premiere Oncology
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
Santa Rosa : Redwood Regional Medical Group
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Santa Rosa : Redwood Regional
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Santa Rosa : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Santa Rosa : Research Site Updated
Video Impact on Neulasta Education
South San Francisco :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
South San Francisco :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Stanford : Stanford University Medical Center Stanford Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Stanford :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Stanford : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Stanford : Stanford University - Stanford Breast Imaging Center
Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System
Stanford : Stanford University Medical Center
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
Stanford : Stanford University
Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
Stanford :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Stanford : Site Reference ID/Investigator# 65488
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Sylmar : University of California at Los Angeles
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Truckee : Tahoe Forest Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Valencia : Granada Hills Cancer Center
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Vallejo :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Vallejo :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Vallejo : Research Site Updated
Video Impact on Neulasta Education
Walnut Creek : John Muir/Mt. Diablo Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Walnut Creek :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
West Hills : Wellness Oncology Hematology
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Whittier : Presbyterian Intercommunity Hospital
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Colorado
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Aurora : University of Colorado Cancer Center
A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
Aurora : University of Colorado Cancer Center, Anschutz Medical Campus Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Aurora : Aurora Presbyterian Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Aurora :
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
View More »
Aurora : Site Reference ID/Investigator# 60751
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Boulder : Boulder Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Colorado Springs : Memorial Hospital Cancer Center - Colorado Springs
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Colorado Springs : Penrose Cancer Center at Penrose Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Denver :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Denver :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Denver : CCOP, Colorado Cancer Research Program, Inc. Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Denver : Rose Medical Center
Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study
Denver : CCOP - Colorado Cancer Research Program, Inc.
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Denver : Kaiser Permanente Northwest Kaiser
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Denver : St. Anthony Central Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : Porter Adventist Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : Rose Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : St. Joseph Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : Presbyterian - St. Luke's Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : CCOP - Colorado Cancer Research Program
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Englewood : Swedish Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Collins : Front Range Cancer Specialists
Dose-escalation Study of Oral CX-4945
Fort Collins : Poudre Valley Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Collins : Front Range Cancer Specialists
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Golden : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Grand Junction : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Grand Junction : St. Mary's Cancer Center St Mary's
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Grand Junction : St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greeley : North Colorado Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenwood Village : Rocky Mountain Cancer Centers RMCC Hale Pkwy Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Greenwood Village : Rocky Mountain Cancer Centers RMCC - Denver-Midtown
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Littleton : Littleton Adventist Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lone Tree : Sky Ridge Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Longmont : Hope Cancer Care Center at Longmont United Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Loveland : Front Range Cancer Specialists
Dose-escalation Study of Oral CX-4945
Loveland : McKee Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Parker : Parker Adventist Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pueblo : St. Mary - Corwin Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Thornton : North Suburban Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wheat Ridge :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Wheat Ridge : Exempla Lutheran Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Connecticut
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Bridgeport : Bridgeport Hospital
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Bridgeport :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Hartford : Hartford Hospital
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Hartford : Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Middletown :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
New Haven : Yale Comprehensive Cancer Center at Yale University School of Medicine
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
New Haven : Smilow Hospital Breast Center
Breast Cancer Molecular Analysis Protocol
New Haven : Yale Cancer Center
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
New Haven : Yale University, Yale Cancer Center
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
New Haven :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Norwalk :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Norwalk : Norwalk Hospital Whittingham Cancer Ctr.
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Norwich :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Norwich : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Stamford :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Stamford : Stamford Hospital, Bennett Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Stamford : Stamford Hospital
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Stamford : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Waterbury : Waterbury Hospital Health Center
Computed Tomography Laser Mammography Breast Imaging Device
Delaware
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Lewes : Tunnell Cancer Center at Beebe Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newark : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Newark : GSK Investigational Site
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
Newark : Helen F. Graham Cancer Center
Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
View More »
Newark : CCOP - Christiana Care Health Services
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
District of Columbia
Washington :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Washington :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Washington : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Washington :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Washington : Georgetown Lombardi Comprehensive Cancer Center
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
View More »
Washington : Washington Hospital Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Washington :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Washington : Sibley Memorial Hospital
Vaccine Therapy in Treating Patients With Breast Cancer
Florida
Fort Lauderdale : Holy Cross Hospital
ECOG E5508
Fort Lauderdale : Holy Cross Hospital
M12-895
Fort Lauderdale : Holy Cross Hospital
Nipple Sparing
Fort Lauderdale : Holy Cross Hospital
NOLAN Study
Fort Lauderdale : Holy Cross Hospital
NSABP B-49
Fort Lauderdale : Holy Cross Hospital
PRESENT
Fort Lauderdale : Holy Cross Hospital
SWOG S1007
Fort Lauderdale : Holy Cross Hospital
VINE Study
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Boca Raton :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Boca Raton : Site Reference ID/Investigator# 60749
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Boynton Beach : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Clearwater : Morton Plant Mease Health Care
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Coral Springs : Mary Beth Tomaselli
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Fort Lauderdale : Holy Cross Hospital-Michael & Dianne Bienes Comprehensive Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Fort Lauderdale : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Fort Lauderdale : Broward General Medical Center Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Lauderdale : Site Reference ID/Investigator# 62995
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Fort Lauderdale : Research Site Updated
Video Impact on Neulasta Education
Fort Myers :
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Fort Myers :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Fort Myers :
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Fort Myers :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Fort Myers : 21st Century Oncology
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Fort Myers :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Fort Myers : Florida Cancer Specialists
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Hollywood : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Hollywood :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Hollywood :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Hollywood : Memorial Regional Cancer Center MRCC
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Jacksonville : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Jacksonville :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Jacksonville :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Jacksonville : Cancer Specialists of North Florida (ICON) Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Jacksonville : Baptist Medical Center South
Patient Controlled Tissue Expansion for Breast Reconstruction
Jacksonville : Baptist Cancer Institute - Jacksonville
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Jacksonville : Florida Oncology Associates Orange Park
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Jacksonville :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Lake Worth : The Breast Institute at JFK Medical Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Lake Worth : Cancer Center of South Florida
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Lakeland :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Lakeland : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Miami :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Miami :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Miami :
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols
Miami : Baptist Health South Florida
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Miami : University of Miami
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
Miami : University of Miami Univ Miami 2
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Miami Beach : CCOP - Mount Sinai Medical Center Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
New Port Richey : Pasco Hernando Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
New Port Richey : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Ocala :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Orlando : MD Anderson Cancer Center- Orlando Updated
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Orlando :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Orlando : MD Anderson Center-Orlando health Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Orlando : MD Anderson Cancer Center - Orlando MD Orlando
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Pembroke Pines :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Pensacola : Sacred Heart Cancer Center at Sacred Heart Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pensacola : Sacred Heart Medical Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Plantation :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Plantation : Florida Cancer Research Institute
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Plantation :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Plantation : Florida Cancer Research Institute (Florida Cancer Care) Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Plantation : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Plantation : Florida Cancer Research Institute
Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
Port St. Lucie :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Sarasota : Sarah Cannon Research Institute
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor
Sarasota :
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Sarasota : Florida Cancer Specialists
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
Savannah : Center for Breast Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
St. Petersburg :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
St. Petersburg :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Stuart : Martin Memorial Health Systems, Stuart - Robert & Carol Weissman Cancer Center
Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System
Stuart : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Tampa :
A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer
Tampa : H. Lee Moffitt Cancer Center and Research Institute
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
Tampa : H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Tampa : H. Lee Moffitt Cancer Center/University of South Florida SC Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Tampa : H.Lee Moffitt Cancer Center and Research Institute Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Tampa : University of South Florida Breast Cancer Program
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Tampa : H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tampa :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Tampa : Site Reference ID/Investigator# 60746
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Tampa : H. Lee Moffitt Cancer Center/University of South Florida H. Lee Moffitt SC
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Titusville :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Titusville : Space Coast Medical Associates
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
West Palm Beach :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
West Palm Beach : Site Reference ID/Investigator# 60762
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Georgia
Savannah : Memorial University Medical Center
CCCWFU 97609: Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity.
Savannah : Memorial University Medical Center
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy.
Savannah : Memorial University Medical Center
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative Her2-Low Invasive Breast Cancer
Savannah : Memorial University Medical Center
NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Savannah : Memorial University Medical Center
RTOG 1005: A Phase III Trial of Accelerated Whole Breast Irradiation with Hypo-fractionation Plus Concurrent Boost versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
Savannah : Memorial University Medical Center
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Savannah : Memorial University Medical Center
SWOG S1105: Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Albany :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Albany : Phoebe Putney Memorial Hospital Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Athens : Northeast Georgia Cancer Care
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Athens : Northeast Georgia Cancer Care Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Atlanta : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Atlanta : Taofeek Owonikoko, MD, PhD
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Atlanta :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Atlanta :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Atlanta : Piedmont Healthcare
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Atlanta :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Atlanta : Emory University Healthcare
Collection of FUJIFILM's 3Dimensional Mammograms
Atlanta : Emory University Winship Cancer Institute
Exemestane or Docetaxel-cytoxan in Low Recurrence Score Cancers
Atlanta : Emory University
Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Atlanta : Emory University Winship Cancer Institute
Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer
Atlanta : Emory University Winship Cancer Institute
Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer
Atlanta : Emory University Winship Cancer Institute
Re-expression of ER in Triple Negative Breast Cancers
Atlanta : Northside Hospital Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Atlanta : Saint Joseph's Hospital of Atlanta
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Atlanta : CCOP - Atlanta Regional
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Atlanta : Piedmont Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Atlanta : Emory University Winship Cancer Institute
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Austell : WellStar Cobb Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Carrolton :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Columbus : John B. Amos Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Decatur : Dekalb Medical
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Decatur : Georgia Cancer Specialists Georgia Cancer
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Decatur : Charles B. Eberhart Cancer Center at DeKalb Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fayetteville : Piedmont Fayette Hospital
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Fayetteville : Piedmont Fayette Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Gainesville : Northeast Georgia Medical Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Gainesville : Northeast Georgia Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lawrenceville : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Lawrenceville : Suburban Hematology-Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Lawrenceville : Gwinnett Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Macon : Central Georgia Cancer Care Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Marietta :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Marietta :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Marietta : Northwest Georgia Oncology Center NW Georgia Onc Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Marietta : Georgia Cancer Specialists
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Marietta :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Marietta : Advanced Breast Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Marietta : Kennestone Cancer Center at Wellstar Kennestone Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Marietta :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Riverdale : Southern Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Rome : Harbin Clinic Cancer Center - Medical Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Savannah :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Savannah : Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Thomasville : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Valdosta : Pearlman Comprehensive Cancer Center at South Georgia Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hawaii
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Aiea : Kapiolani Medical Center at Pali Momi
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Kaiser Permanente Hawaii
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Honolulu : Tripler Army Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : OnCare Hawaii, Incorporated - Lusitana
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Honolulu : Kapiolani Medical Center for Women and Children
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : OnCare Hawaii, Incorporated - Kuakini
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Straub Clinic and Hospital, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Hawaii Medical Center - East
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Queen's Cancer Institute at Queen's Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Cancer Research Center of Hawaii
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : University of Hawaii Cancer Center
Vaccine Therapy in Treating Patients With Breast Cancer
Lihue : Kauai Medical Clinic
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wailuku : Maui Memorial Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wailuku : Pacific Cancer Institute - Maui
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Idaho
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Boise : Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Boise : Mountain States Tumor Institute at St. Luke's Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fruitland : Saint Luke's Mountain States Tumor Institute - Fruitland
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lewiston : St. Joseph Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Meridian : Mountain States Tumor Institute - Meridian
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Nampa : Saint Luke's Mountain States Tumor Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Post Falls :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Post Falls : Kootenai Cancer Center
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Twin Falls : Mountain States Tumor Institute at St. Luke's
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Illinois
Chicago : Northwestern University
Dose finding and tolerability study of alpha-lipoic acid in patients at risk for paclitaxel induced peripheral neuropathy
Elgin : Sherman Health
ECOG E2108 Phase III Randomized Study of Early Local Therapy Comprising Surgery Versus Standard Palliative Therapy for the Intact Primary Tumor in Patients With Stage IV Breast Cancer
Elgin : Sherman Health
ECOG E3108 Phase II Prospective Study of CYP2D6 Activity in Patients With Metastatic or Recurrent Breast Cancer Treated With Tamoxifen Citrate
Elgin : Sherman Health
NSABP B-47 Phase III Randomized Study of Adjuvant Chemotherapy With Versus Without Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Elgin : Sherman Health
NSABP B-49 Phase III Study of Docetaxel and Cyclophosphamide Versus Anthracycline-Based Chemotherapy Regimens in Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Elgin : Sherman Health
NSABP DMP-1 A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer
Elgin : Sherman Health
NSABP MA.32 Ancillary Study of Biobehavioral Mechanisms of Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride Versus Placebo on NCIC-CTG-MA.32
Elgin : Sherman Health
RTOG 1005 Phase III Randomized Study of Accelerated Hypofractionated Whole-Breast Irradiation and Concurrent Boost Versus Standard Whole-Breast Irradiation and Sequential Boost in Patients With Early-Stage Breast Cancer After Lumpectomy
Elgin : Sherman Health
SWOG S0800 Phase II Randomized Study of Neoadjuvant Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin Hydrochloride, Cyclophosphamide, and Pegfilgrastim With Versus Without Bevacizumab in Women With HER2/neu-Negative Inflammatory or Locally Advanced Breast Cancer
Elgin : Sherman Health
SWOG S1007 Phase III Randomized Study of Standard Adjuvant Endocrine Therapy With Versus Without Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive, and HER2-Negative Breast Cancer
Elgin : Sherman Health
SWOG S1105 Randomized Study of Text-Messaging Intervention in Reducing Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Stage I, II, or III Breast Cancer
Elk Grove Village : Alexian Brothers Hospital Network
A multicenter, open-label, randomized trial to evaluate the anti-cancer effects of zoledronic acid and circulating tumor cell measurements in patients with HER2-negative metastatic breast cancer without bone metastasis
Elk Grove Village : Alexian Brothers Hospital Network
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Elk Grove Village : Alexian Brothers Hospital Network
A randomized study to prevent lymphedema in women treated for breast cancer
Elk Grove Village : Alexian Brothers Hospital Network
NSABP PROTOCOL B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Elk Grove Village : Alexian Brothers Hospital Network
NSABP PROTOCOL B-43 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Additional Locations : Cancer Care and Hematology Specialists of Chicagoland Niles
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Alton :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Aurora : Rush-Copley Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bloomingdale : Advanced Breast Care Specialists
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Carbondale : Memorial Hospital of Carbondale
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Chicago : University of Chicago Medical Center University of Chicago (16)
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Chicago : University Of Chicago Medical Center Updated
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Chicago :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Chicago : University Of Chicago
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Chicago : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Chicago : Northwestern University Feinberg School of Medicine, Lynn Sage Comprehensive Breast Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Chicago : University of Chicago
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Chicago : Northwestern University
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
Chicago : Vanguard Health Chicago
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Chicago : Advocate Illinois MasonicMedical Cent/Creticos Cancer Center Dept. of Creticos Cancer Cente
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Chicago : Louis A. Weiss Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Chicago : John H. Stroger, Jr. Hospital of Cook County
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Chicago : Site Reference ID/Investigator# 60755
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Chicago : Site Reference ID/Investigator# 65489
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Chicago : Site Reference ID/Investigator# 60757
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Chicago : Northwestern University
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Chicago : University of Chicago
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Chicago : Research Site Updated
Video Impact on Neulasta Education
Decatur :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Decatur : Decatur Memorial Hospital Cancer Care Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elgin : Sherman Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elk Grove Village : University Surgical Consultants
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Elmhurst : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Evanston : North Shore University Health System
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Evanston : Evanston Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Geneva : Cadence Health
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Geneva : Delnor Hospital - Geneva
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Harvey :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Hines : Veterans Affairs Medical Center - Hines
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Joliet :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Joliet :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Maywood :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Maywood : Cardinal Bernardin Cancer Center at Loyola University Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Moline :
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Moline : Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mount Vernon : Good Samaritan Regional Health Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Naperville : Edward Hospital Edward Hospital
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Naperville :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Naperville : Edward Cancer Center
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Niles : Illinois Cancer Specialists
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Normal :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Park Ridge :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Park Ridge : Advocate Lutheran General Hospital
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Park Ridge : Oncology Specialists, SC Lutheran General Advanced Care
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Peoria :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Peoria :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Peoria : Research Site Updated
Video Impact on Neulasta Education
Plainfield : Edward Cancer Center Plainfield
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
River Forest : West Suburban Center for Cancer Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Skokie :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Springfield : Regional Cancer Center at Memorial Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Urbana :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Urbana :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Urbana : Carle Foundation Hospital
Real Time Optical Coherence Tomography (OCT) of Human Tissue
Urbana : CCOP - Carle Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Warrenville : Central Dupage Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Yorkville : Yorkville Family Practice
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Zion : Site Reference ID/Investigator# 60744
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Indiana
Anderson : Community Clinical Research Center
A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Anderson : Community Hospital of Anderson
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Beech Grove : St. Francis Hospital and Health Centers - Beech Grove Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elkhart : Elkhart Clinic, LLC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elkhart : Elkhart General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elkhart : Michiana Hematology-Oncology, PC - Elkhart
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Evansville :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Evansville : Evansville Surgical Associates
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Evansville : Research Institute of Deaconess Clinic
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Goshen : IU Health Goshen Cancer Center
Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
Indianapolis : Inidiana University Melvin and Bren Simon Cancer Center
A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
Indianapolis : Indiana University
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Indianapolis : Indiana University
Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
Indianapolis : St. Vincent Hospital and Health Care Center
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Indianapolis : University of Indiana
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Kokomo : Howard Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
La Porte : Center for Cancer Therapy at LaPorte Hospital and Health Services
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Michigan City : Saint Anthony Memorial Health Centers
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mishawaka : Michiana Hematology-Oncology, PC - South Bend
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mishawaka : Saint Joseph Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
New Albany : Cancer Care Center
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Plymouth : Michiana Hematology Oncology PC - Plymouth
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Richmond : Reid Hospital & Health Care Services
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
South Bend : Northern Indiana Cancer Research
NBRST: Prospective Neo-adjuvant REGISTRY Trial
South Bend : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
South Bend : CCOP - Northern Indiana CR Consortium
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
South Bend : Memorial Hospital of South Bend
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Westville : Michiana Hematology Oncology PC - La Porte
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Iowa
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Ames :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Ames : McFarland Clinic, PC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bettendorf :
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cedar Rapids : Mercy Regional Cancer Center at Mercy Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Cedar Rapids : Cedar Rapids Oncology Associates
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Clive : Medical Oncology and Hematology Associates - West Des Moines
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Davenport : Genesis Regional Cancer Center at Genesis Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : CCOP - Iowa Oncology Research Association
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : Medical Oncology and Hematology Associates at Mercy Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : John Stoddard Cancer Center at Iowa Lutheran Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : Mercy Cancer Center at Mercy Medical Center - Des Moines
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : John Stoddard Cancer Center at Iowa Methodist Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : Medical Oncology and Hematology Associates at John Stoddard Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dubuque : Medical Associates Clinic, PC
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Iowa City :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Mason City :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Mason City : Mercy Cancer Center at Mercy Medical Center - North Iowa
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mason City : Research Site Updated
Video Impact on Neulasta Education
Sioux City :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Sioux City : Siouxland Hematology-Oncology Associates LLP
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Sioux City : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Sioux City : Mercy Medical Center - Sioux City
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sioux City : Siouxland Hematology-Oncology Associates, LLP
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sioux City : St. Luke's Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Waterloo : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Kansas
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Chanute : Cancer Center of Kansas, PA - Chanute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dodge City : Cancer Center of Kansas, PA - Dodge City
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
El Dorado : Cancer Center of Kansas, PA - El Dorado
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Scott : Cancer Center of Kansas - Fort Scott
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Hays : Hays Medical Center
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Independence : Cancer Center of Kansas-Independence
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : University of Kansas Cancer Center Univ Kansas 2 Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Kansas City : University of Kansas Medical Center Cancer Center
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Kansas City : University of Kansas Medical Center
Radiofrequency Ablation After Breast Lumpectomy (ABLATE)
Kansas City : University of Kansas Medical Center
Study of Breast Cancer Prevention by Letrozole in High Risk Women
Kingman : Cancer Center of Kansas, PA - Kingman
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lawrence : Lawrence Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Liberal : Cancer Center of Kansas, PA - Liberal
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
McPherson : Cancer Center of Kansas, PA - McPherson
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newton : Cancer Center of Kansas, PA - Newton
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Overland Park : Saint Luke's Hospital - South
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Overland Park : Menorah Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Overland Park : Kansas City Cancer Centers
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Parsons : Cancer Center of Kansas, PA - Parsons
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Prairie Village : CCOP - Kansas City
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pratt : Cancer Center of Kansas, PA - Pratt
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salina : Tammy Walker Cancer Center at Salina Regional Health Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salina : Cancer Center of Kansas, PA - Salina
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Topeka : Cotton-O'Neil Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wellington : Cancer Center of Kansas, PA - Wellington
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Westwood : The University of Kansas Cancer Center
Excision Followed by Radiofrequency Ablation for Breast Cancer
Wichita : Cancer Center of Kansas Dept.ofCancerCtr.ofKansas
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Wichita :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Wichita :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Wichita : Cancer Center of Kansas
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Wichita : Cancer Center of Kansas Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Wichita : Cancer Center of Kansas CCK
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Wichita : Cancer Center of Kansas, PA - Medical Arts Tower
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : Associates in Womens Health, PA - North Review
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : CCOP - Wichita
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : Via Christi Cancer Center at Via Christi Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : Cancer Center of Kansas, PA - Wichita
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Winfield : Cancer Center of Kansas, PA - Winfield
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kentucky
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Hazard : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Hazard : Kentucky Lung Clinic & Kentucky Sleep Clinic
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Lexington : University of Kentucky Medical Center
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Louisville : Norton Healthcare, Inc. Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
View More »
Louisville :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Louisville : James Graham Brown Cancer Center, University of Louisville Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Mount Sterling : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Mount Sterling : Sandoz Investigational Site
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Paducah : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Louisiana
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Alexandria : Cabrini Center for Cancer Care
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Alexandria : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Baton Rouge :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Baton Rouge : Mary Bird Perkins Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
View More »
Baton Rouge : Ochsner Health Center - Bluebonnet
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Covington : Ochsner Health Center - Covington
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lafayette :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Lafayette : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Marrero : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Marrero :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Metairie : Hematology and Oncology Specialists SC
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Metairie :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Monroe : Louisiana State University Health Sciences Center - Monroe
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
New Orleans : Ochsner Cancer Institute at Ochsner Clinic Foundation
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
New Orleans : CCOP - Ochsner
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Shreveport : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Shreveport : Highland Clinic
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Shreveport : Feist-Weiller Cancer Center at Louisiana State University Health Sciences
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Maine
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Bangor :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Portland :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Scarborough :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Maryland
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Baltimore :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Baltimore :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Baltimore : Johns Hopkins Hospital
Computed Optical Margin Assessment for Breast Cancer Surgery
Baltimore : Greenbaum Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
View More »
Baltimore : Johns Hopkins
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Baltimore : Mercy Medical Center Mercy Medical SC
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Baltimore : Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Sidney/John Hopkins
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Baltimore :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Baltimore : Site Reference ID/Investigator# 60748
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Baltimore : Site Reference ID/Investigator# 92633
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Baltimore : Site Reference ID/Investigator# 91213
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Baltimore : Site Reference ID/Investigator# 60759
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Baltimore : MedStar Good Samaritan Hospital Cancer Center
Vaccine Therapy in Treating Patients With Breast Cancer
Baltimore : MedStar Union Memorial Hospital
Vaccine Therapy in Treating Patients With Breast Cancer
Bethesda :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Bethesda : Center for Cancer & Blood Disorders
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Bethesda : Center of Cancer and Blood Disorders (VEEDA network) Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Bethesda : NCI, CCR
Open Label Study to Evaluate the Safety and Tolerability of GI-6301 (Whole Heat-Killed Recombinant Yeast Modified to Express Brachyury Protein) in Adults With Solid Tumors
Bethesda : Walter Reed National Military Medical Center
Vaccine Therapy in Treating Patients With Breast Cancer
Cumberland :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Cumberland : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Elkton : Union Hospital of Cecil County
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Frederick : Frederick Memorial Hospital Fred. Mem. Hosp.
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Lanham : Signature Breast Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Randallstown : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Rockville :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Rockville : Associates in Oncology/Hematology, P.C. SC
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Silver Spring : Holy Cross Hospital Holy Cross
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Silver Spring :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Westminster :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Westminster : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Massachusetts
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Boston : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Boston : Massachusetts General Hospital SC-5
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Boston : Massachusetts General Hospital
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Boston : Massachusetts General Hospital Mass General 2 Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
View More »
Boston : Dana-Farber Cancer Institute
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor
Boston :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Boston :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Boston : Dana Farber Cancer Institute
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Boston : Dana-Farber Cancer Institute
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Boston : Massachusetts General Hospital Updated
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Boston : Beth Israel Deaconess Medical Center Updated
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Boston : Dana Farber Cancer Institute Updated
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Boston : Beth Israel Deaconess Medical Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Boston : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Boston : Dana Farber Cancer Institute
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Boston : Dana-Farber at Faulkner Hospital
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Boston : Dana-Farber Cancer Institute
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Boston : Beth Israel Deaconess Medical Center
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Boston : Massachusetts General Hospital
Patient Controlled Tissue Expansion for Breast Reconstruction
Boston : Faulkner Hospital
Patient Controlled Tissue Expansion for Breast Reconstruction
Boston : Beth Israel Deaconess Medical Center
Patient Controlled Tissue Expansion for Breast Reconstruction
Boston : Tufts Cancer Center
Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
Boston : Massachusetts General Hospital SC
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Boston : Dana-Farber at Faulkner Hospital
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Boston : Massachusetts General Hospital
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Boston : Dana-Farber Cancer Institute
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Boston : Dana Farber Cancer Center
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Boston : Massachusetts General Hospital
Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Boston :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Boston :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Boston : Site Reference ID/Investigator# 64582
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Boston : Massachusetts General Hospital
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Boston : Dana-Farber Cancer Institute at Faulkner Hospital
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Boston : Dana-Farber Cancer Institute
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Boston : Beth Israel Deaconess Medical Center
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Boston : Massachusetts General Hospital
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Burlington : Lahey Clinic Department of Hematology and Oncology Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Fairhaven : Research Site Updated
Video Impact on Neulasta Education
Methuen : Caritas Holy Family Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pittsfield :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Worcester : University of Massachusetts Memorial Medical Center
Patient Controlled Tissue Expansion for Breast Reconstruction
Michigan
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Adrian : Hickman Cancer Center at Bixby Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Ann Arbor : CCOP - Michigan Cancer Research Consortium
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Ann Arbor : Saint Joseph Mercy Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Ann Arbor : University of Michigan Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Battle Creek : Battle Creek Health System Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bay City : Bay Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Big Rapids : Mecosta County Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dearborn : Oakwood Cancer Center at Oakwood Hospital and Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Detroit : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Detroit :
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Detroit : Karmanos Cancer Institute
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor
Detroit :
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Detroit : Henry Ford Health System Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Detroit : Sandoz Investigational Site
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Detroit : Josephine Ford Cancer Center at Henry Ford Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Detroit : Karmanos Cancer Center
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Detroit :
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Escanaba : Green Bay Oncology, Limited - Escanaba
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Flint : McLaren Cancer Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Flint : Hurley Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Flint : Genesys Hurley Cancer Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Flint : Singh and Arora Hematology Oncology, PC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grand Rapids :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Grand Rapids :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Grand Rapids : CCOP - Grand Rapids
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grand Rapids : Butterworth Hospital at Spectrum Health
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grand Rapids : Lacks Cancer Center at Saint Mary's Health Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grosse Pointe Woods : Great Lakes Cancer Management Specialists
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Grosse Pointe Woods : Van Elslander Cancer Center at St. John Hospital and Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Iron Mountain : Dickinson County Healthcare System
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Jackson : Foote Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalamazoo :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Kalamazoo :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Kalamazoo : West Michigan Cancer Center Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Kalamazoo : West Michigan Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalamazoo : Borgess Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalamazoo : Bronson Methodist Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lansing : Sparrow Regional Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lansing : Breslin Cancer Center at Ingham Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lansing : Site Reference ID/Investigator# 71193
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Lapeer : Great Lakes Cancer Institute - Lapeer Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Livonia : St. Mary Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Monroe : Community Cancer Center of Monroe
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Monroe : Mercy Memorial Hospital - Monroe
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mount Clemens : Clemens Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Muskegon : Mercy General Health Partners
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Petoskey : Northern Michigan Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pontiac : St. Joseph Mercy Oakland
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Port Huron : Mercy Regional Cancer Center at Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Reed City : Spectrum Health Reed City Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Royal Oak : Beaumont Health Systems
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Royal Oak : William Beaumont Hospital - Royal Oak Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Royal Oak : William Beaumont Hospital
Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB
Saginaw : Seton Cancer Institute at Saint Mary's - Saginaw
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Southfield : Providence Hospital - Southfield Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Southfield : Providence Cancer Institute at Providence Hospital - Southfield Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Joseph : Lakeside Cancer Specialists, PLLC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Joseph : Lakeland Regional Cancer Care Center - St. Joseph
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Traverse City : Munson Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Warren : St. John Macomb Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Minnesota
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Brainerd : St. Joseph's Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Burnsville : Fairview Ridges Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Coon Rapids : Mercy and Unity Cancer Center at Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Duluth : CCOP - Duluth
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Duluth : Miller - Dwan Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Duluth : Duluth Clinic Cancer Center - Duluth
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Edina :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Edina : Fairview Southdale Medical Oncology Clinic
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Edina : Fairview Southdale Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fridley : Mercy and Unity Cancer Center at Unity Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hutchinson : Hutchinson Area Health Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Maplewood : HealthEast Cancer Care at St. John's Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Maplewood : Minnesota Oncology - Maplewood
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Minneapolis : Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Minneapolis : Hennepin County Medical Center - Minneapolis
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
New Ulm : New Ulm Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Robbinsdale : Humphrey Cancer Center at North Memorial Outpatient Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Paul : United Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Shakopee : St. Francis Cancer Center at St. Francis Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Cloud :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
St. Louis Park :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
St. Louis Park :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
St. Louis Park : CCOP - Metro-Minnesota
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
St. Louis Park : Park Nicollet Institute Dept Onc
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
St. Louis Park : Park Nicollet Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis Park : CCOP - Metro-Minnesota
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Paul : Regions Hospital Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Stillwater : Lakeview Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Waconia : Ridgeview Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Willmar : Willmar Cancer Center at Rice Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Woodbury : Minnesota Oncology - Woodbury
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mississippi
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Jackson :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Jackson : University of Mississippi Cancer Clinic
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Jackson : Veterans Affairs Medical Center - Jackson
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pascagoula : Regional Cancer Center at Singing River Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Tupelo : Hematology and Oncology Association at Bridgepoint Hem Onc Bridgeport
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Missouri
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Cape Girardeau : Southeast Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cape Girardeau : Saint Francis Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbia : University of Missouri-Ellis Fischel
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Jefferson City :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
View More »
Jefferson City : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Jefferson City : Goldschmidt Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Jefferson City : Research Site Updated
Video Impact on Neulasta Education
Kansas City : St Lukes Cancer Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Kansas City : Research Medical Center Reseach Med Ctr
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Kansas City : North Kansas City Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Saint Luke's Cancer Institute at Saint Luke's Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Veterans Affairs Medical Center - Kansas City
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Heartland Hematology Oncology Associates, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Research Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lee's Summit : Saint Luke's East - Lee's Summit
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Liberty : Parvin Radiation Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Manchester : Mercy Medical Research Institute SC
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
St. Joseph : Saint Joseph Oncology, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Joseph : Heartland Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis : Washington University School Of Medicine-Siteman Cancer Ctr SC
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
St. Louis :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
St. Louis :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
St. Louis : Washington University School Of Medicine-Siteman Cancer Ctr Was Univ School of Med Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
St. Louis :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
St. Louis : Christian Hospital
NBRST: Prospective Neo-adjuvant REGISTRY Trial
St. Louis : Missouri Baptist Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis : Christian Hospital Northeast Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis : David C. Pratt Cancer Center at St. John's Mercy
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis : CCOP - St. Louis-Cape Girardeau
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis : Saint Louis University Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis : Midwest Hematology Oncology Group, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
St. Louis : Site Reference ID/Investigator# 62724
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
St. Louis : Bodyaesthetic
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
St. Louis : Research Site Updated
Video Impact on Neulasta Education
Montana
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Billings :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Billings :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Billings : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Billings : CCOP - Montana Cancer Consortium
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Billings : St. Vincent Healthcare Cancer Care Services
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Billings : Billings Clinic - Downtown
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Billings : Hematology-Oncology Centers of the Northern Rockies - Billings
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bozeman : Bozeman Deaconess Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Butte : St. James Healthcare Cancer Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Great Falls : Sletten Cancer Institute at Benefis Healthcare
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Great Falls : Big Sky Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Helena : St. Peter's Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalispell : Kalispell Medical Oncology at KRMC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalispell : Kalispell Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Missoula :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Missoula : Montana Cancer Specialists at Montana Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Missoula : Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Nebraska
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Grand Island : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Hastings : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Kearney : Good Samaritan Cancer Center at Good Samaritan Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lincoln :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
View More »
Lincoln :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Lincoln : Southeast Nebraska Oncology Cancer Center
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Lincoln : Cancer Resource Center - Lincoln
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Omaha :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Omaha :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Omaha : University of Nebraska
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Omaha : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Omaha : Lakeside Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : Immanuel Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : Alegant Health Cancer Center at Bergan Mercy Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : Creighton University Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : CCOP - Missouri Valley Cancer Consortium
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : Methodist Cancer Center Methodist Estabrook
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Nevada
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Henderson : Comprehensive Cancer Centers of Nevada
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Las Vegas : Compehensive Cancer Care of Nevada
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Las Vegas : University Medical Center of Southern Nevada
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Las Vegas : Nevada Cancer Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Las Vegas : CCOP - Nevada Cancer Research Foundation
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Las Vegas :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Syracuse :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
New Hampshire
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Hooksett : New Hampshire Oncology-Hematology PA
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Lebanon :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Lebanon :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Lebanon : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
View More »
Nashua : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Portsmouth :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Portsmouth : Research Site Updated
Video Impact on Neulasta Education
New Jersey
Paramus : The Valley Hospital/Valley Health System
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Basking Ridge : Memorial Sloan-Kettering at Basking Ridge
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Basking Ridge :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Basking Ridge : Memorial Sloan-Kettering at Basking Ridge
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Berkeley Heights :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Brick : Meridian Health Systems
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Denville :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Hackensack :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Livingston : Saint Barnabas Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Livingston : Saint Barnabas Medical Center CancerCenter of Saint Barnabas
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Morristown :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Morristown :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Morristown :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Morristown : Research Site Updated
Video Impact on Neulasta Education
New Brunswick : Cancer Institute of New Jersey Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
Internal Radiation Therapy of the Breast in Treating Women With Early-Stage Breast Cancer
New Brunswick : Cancer Institute of New Jersey
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
New Brunswick : Cancer Institute of New Jersey
Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB
New Brunswick : Site Reference ID/Investigator# 62783
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Newark : UMDNJ University Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Paramus :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Paramus : The Valley Hospital / Luckow Pavillion
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Voorhees : CINJ at Cooper University Hospital Dept of Onc
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Voorhees :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Voorhees : Cooper Cancer Institute
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Voorhees : Cancer Institute of New Jersey at Cooper - Voorhees
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Willingboro : Virtua Health
NBRST: Prospective Neo-adjuvant REGISTRY Trial
New Mexico
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Albuquerque : University of New Mexico Cancer Center
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Albuquerque : Hematology Oncology Associates, PC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Albuquerque : University of New Mexico Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Albuquerque : Research Site Updated
Video Impact on Neulasta Education
View More »
Las Cruces : Memorial Medical Center
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
New York
Jamaica : Biomedical Research Alliance of New York
HER2-positive Locally Recurrent or Metastatic Breast Cancer
Lake Success : Biomedical Research Alliance of New York
Breast Cancer
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Albany :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Bronx : Montefiore Medical Center Montefiore
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Bronx :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Bronx : Montefiore Medical Center -Department of Medical Oncology
A Study of Triciribine Phosphate Monohydrate (TCN-PM)
Bronx : Eastchester Cancer Care Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Bronx : Montefiore Medical Center
Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis
Buffalo :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Buffalo : Roswell Park Cancer Institute
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Commack :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Cooperstown :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Cooperstown : Research Site Updated
Video Impact on Neulasta Education
Cortlandt Manor : Ashikari Breast Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
East Setauket :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
East Syracuse : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
East Syracuse : CCOP - Hematology-Oncology Associates of Central New York
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elmira : Falck Cancer Center at Arnot Ogden Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Garden City : Long Island Plasic Surgical Group, PC
Feasibility Study of Meso BioMatrix Device for Breast Reconstruction
Glenn Falls : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Glens Falls : Research Site Updated
Video Impact on Neulasta Education
Great Neck : Arena Oncology Associates, PC
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Great Neck : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Great Neck : Aesthetic Plastic Surgery
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Johnson City : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Lake Success :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Lake Success : Arena Oncology Associates, PC SC
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Lake Success : ProHealth Care
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
New York : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
New York :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
New York :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
New York : Memorial Sloan Kettering Cancer Center Updated
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
New York : Memorial Sloan-Kettering Cancer Center
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
New York : Memorial Sloan-Kettering Cancer Center
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
New York : Weill Cornell Medical College Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
New York : Columbia
Excision Followed by Radiofrequency Ablation for Breast Cancer
New York : Memorial Sloan Kettering Cancer Center Updated
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
New York : Memorial Sloan Kettering Cancer Center
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
New York : Columbia University
Patient Controlled Tissue Expansion for Breast Reconstruction
New York : Weill Cornell/New York Presbyterian Hospital
Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
New York : Memorial Sloan Kettering Cancer Center Dept Onc
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
New York : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
New York :
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
New York : Memorial Sloan-Kettering Cancer Center
Safety Study of Topical Compound 31543 (Calcitriol, USP) in Patients Receiving Chemotherapy for Breast Cancer
New York : Columbia University
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
New York :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
New York : Weill Cornell Breast Center
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
New York : Memorial Sloan Kettering Cancer Center
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
New York : Site Reference ID/Investigator# 87973
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
New York : Site Reference ID/Investigator# 87993
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
New York : Site Reference ID/Investigator# 63222
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
New York : Site Reference ID/Investigator# 60756
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
New York : Memorial Sloan-Kettering Cancer Center
Tobacco Dependence in Breast Cancer Patients Scheduled for Mastectomy/Reconstructive Surgery Trial of Varenicline (Chantix)
New York : Memorial Sloan Kettering Cancer Center
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
New York : Memorial Sloan Kettering Cancer Center
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
Oceanside : South Nassau Communities Hospital
Patient Controlled Tissue Expansion for Breast Reconstruction
Rochester : Elizabeth Wende Breast Care
Cone Beam Computed Tomography for Breast Imaging
Rochester : University of Rochester Medical Center Highland Breast Imaging Center
Koning Breast Computed Tomography Guided Neoadjuvant Treatment Monitoring
Rochester : James P. Wilmot Cancer Center at University of Rochester Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Rockville Centre :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Sleepy Hollow :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Stony Brook : University Hospital and Medical Center - SUNY Stony Brook
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Troy : New York Oncology Hematology, P.C. Dept. of New York Oncology. PC Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Troy : New York Oncology Hematology, P.C. Dept. of New York Oncology. PC
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
North Carolina
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Asheboro : Research Site Updated
Video Impact on Neulasta Education
Asheville : Mission Hospitals - Memorial Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Chapel Hill : UNC Lineberger Comprehensive Cancer Center Updated
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Chapel Hill :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
View More »
Chapel Hill : Lineberger Comprehensive Cancer Center
Study of BKM120 or BEZ235 and Capecitabine in Patients With Metastatic Breast Cancer
Charlotte : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Charlotte : Carolinas Medical Center/Levine Cancer Center Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Charlotte : CCOP Carolinas HealthCare System
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Charlotte : Presbyterian Health Care
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Charlotte : Presbyterian Cancer Center at Presbyterian Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Concord : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Concord : Northeast Oncology Associates
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Durham : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Durham :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Durham : Duke University
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Durham : Duke University Medical Center
Patient Controlled Tissue Expansion for Breast Reconstruction
Durham : Duke University Medical Center
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Durham : Duke Comprehensive Cancer Center
Study of BKM120 or BEZ235 and Capecitabine in Patients With Metastatic Breast Cancer
Durham : Site Reference ID/Investigator# 60747
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Durham : Duke University Medical Center Duke (SC)
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Fayetteville : Research Site Updated
Video Impact on Neulasta Education
Gastonia :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Gastonia : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Goldsboro : Wayne Memorial Hospital, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Goldsboro : Research Site Updated
Video Impact on Neulasta Education
Greensboro :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Hendersonville : Pardee Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hickory :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Hickory : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Huntersville :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Kinston : Kinston Medical Specialists, PA Updated
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Monroe : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Pinehurst :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Pinehurst : FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Raleigh : Tolnitch Surgical Associates
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Rutherfordton : Rutherford Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Shelby : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Statesville : Iredell Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wilmington : MotHER Registry Coordinating Center
An Observational Study Of Pregnancy And Pregnancy Outcomes In Women With Breast Cancer Treated With Herceptin Or Perjeta In Combination With Herceptin During Pregnancy Or Within 6 Months Prior To Conception (MotHER)
Winston-Salem : Wake Forest University Health Sciences Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Winston-Salem : Wake Forest University School of Medicine
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Winston-Salem : Forsyth Regional Cancer Center
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Winston-Salem : Forsyth Regional Cancer Center at Forsyth Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Winston-Salem : Wake Forest University Comprehensive Cancer Center
Vaccine Therapy in Treating Patients With Breast Cancer
North Dakota
Bismarck : St. Alexius Medical Center
A study of an investigational medication for treatment for patients who have or have had breast cancer. The investigational medication is being developed for use after completion of standard of care therapy for early stage breast cancer to potentially prevent recurrence of the cancer.
Bismarck : Legacy Pharma Research
Chemotherapy Induced Anemia in Patients with Metastatic Breast Cancer
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Bismarck : St. Alexius Medical Center, Mid Dakota Clinic, PC Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Bismarck : Sandoz Investigational Site
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Bismarck : Mid Dakota Clinic, P.C. Dept of Oncology
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Ohio
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Akron : McDowell Cancer Center at Akron General Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bowling Green : Wood County Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Canton : Research Site Updated
Video Impact on Neulasta Education
Chillicothe : Adena Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Cincinnati :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Cincinnati : Charles M. Barrett Cancer Center at University Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cincinnati : Oncology Hematology Care, Inc.
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Cleveland :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Cleveland : Case Western Reserve University/University Hospitals of Cleveland
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Columbus : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Columbus :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Columbus :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Columbus : Ohio State Comprehensive Cancer Center/James Cancer Hospital SC-1 Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Columbus : Ohio State University Updated
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Columbus :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Columbus : Grant Medical Center Cancer Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : Doctors Hospital at Ohio Health
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : CCOP - Columbus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : Riverside Methodist Hospital Cancer Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : Mount Carmel Health - West Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : CCOP - Dayton
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Dayton : David L. Rike Cancer Center at Miami Valley Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : Grandview Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : Samaritan North Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : Good Samaritan Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : CCOP - Dayton
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Delaware : Grady Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elyria : Hematology Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elyria : Community Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Findlay : Blanchard Valley Medical Associates
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Franklin : Middletown Regional Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Wayne Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kettering : CCOP - Dayton
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Kettering : Charles F. Kettering Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lancaster : Fairfield Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lima : Lima Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Marietta : Strecker Cancer Center at Marietta Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Massillon : Research Site Updated
Video Impact on Neulasta Education
Maumee : Northwest Ohio Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Middletown :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Middletown : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Middletown : Signal Point Clinical Research Center
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Mount Vernon : Knox Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newark : Licking Memorial Cancer Care Program at Licking Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oregon : Toledo Clinic - Oregon
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oregon : St. Charles Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portsmouth : Southern Ohio Medical Center Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Springfield : Community Hospital of Springfield and Clark County
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sylvania :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Sylvania : Flower Hospital Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tiffin : Mercy Hospital of Tiffin
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : Medical University of Ohio Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : Toledo Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : St. Vincent Mercy Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : CCOP - Toledo Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : Toledo Clinic, Incorporated - Main Clinic
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : St. Anne Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Troy : UVMC Cancer Care Center at Upper Valley Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wauseon : Fulton County Health Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
West Worthington : Hematology/Oncology Consultants Inc.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Westerville : Mount Carmel St. Ann's Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wright-Patterson Afb : United States Air Force Medical Center - Wright-Patterson
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Xenia : Ruth G. McMillan Cancer Center at Greene Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Zanesville : Genesis - Good Samaritan Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oklahoma
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Oklahoma City : University of Oklahoma Health Sciences Center OUHSC 2 Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Oklahoma City : Dr. William Dooley
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Oklahoma City : OU Medical Center Laboratory
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
Oklahoma City : Peggy and Charles Stephenson Cancer Center
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
View More »
Tulsa :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Tulsa : Southwestern Regional Medical Center
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
Oregon
Eugene : Clinical Trials of America, Inc
Women of 18 years or older with histologically proven breast cancer, eligible for neoadjuvant or adjuvant TAC chemotherapy
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Bend : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Bend : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Bend : Cancer Care of the Cascades St. Charles Medical Center
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Bend : Research Site Updated
Video Impact on Neulasta Education
Clackamas : Clackamas Radiation Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Coos Bay : Bay Area Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Eugene : Sandoz Investigational Site
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Grants Pass : Three Rivers Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Gresham : Legacy Mount Hood Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Medford : Providence Cancer Center at PMCC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Medford : Dubs Cancer Center at Rogue Valley Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Milwaukie : Providence Milwaukie Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newberg : Providence Newberg Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oregon City : Willamette Falls Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Oregon Health & Science University SC-5
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Portland : Northwest Cancer Specialists Vancouver Location
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Portland : Northwest Cancer Specialists Vancouver Loc Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Portland :
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Portland : Northwest Cancer Specialists
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Portland : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Portland : OHSU Knight Cancer Institute Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Portland : Northwest Cancer Specialists Portland Loc
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Portland : CCOP - Columbia River Oncology Program
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Legacy Good Samaritan Hospital & Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Providence St. Vincent Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Providence Cancer Center at Providence Portland Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tualatin : Legacy Meridian Park Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pennsylvania
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Allentown : Breast Care Specialists
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Allentown : Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bethlehem : St. Luke's Hospital and Health Network St Luke
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Dunmore :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
View More »
Hershey : Milton S Hershey Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Hershey : Site Reference ID/Investigator# 62723
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Hershey : Penn State Milton S. Hershey Medical Center
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Johnstown : Conemaugh Memorial Hospital-Memorial Medical Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Lancaster :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Langhorne : St. Mary Medical Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Nashville : Tennessee Oncology Updated
Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Philadelphia : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Philadelphia :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Philadelphia :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Philadelphia :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Philadelphia : Albert Einstein Medical Center Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Philadelphia : Thomas Jefferson University, Dept of Radiology
Quantitative Subharmonic Breast Imaging
Philadelphia : Albert Einstein Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Philadelphia :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Philadelphia : Site Reference ID/Investigator# 60753
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Pittsburgh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Pittsburgh : University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Pittsburgh :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Pittsburgh :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Pittsburgh : University of Pittsburgh Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Pittsburgh : Allegheny General Hospital/Allegheny-Singer Research Institute Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Pittsburgh : NSABP Foundation, Inc. Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Pittsburgh : Univerity of Pittsburgh Medical Center (UPMC) Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Pittsburgh : St. Clair Hospital
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Pittsburgh : NSABP Foundation, Inc.
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Pittsburgh : Allegheny Cancer Center at Allegheny General Hospital
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Pittsburgh : University of Pittsburgh
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Pittsburgh : Site Reference ID/Investigator# 60758
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Sayre :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Sayre : Guthrie Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Willow Grove : Abington Hematology Oncology Associates, Inc Abington Hem Onc
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
York : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
York : York Hospital
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Rhode Island
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Providence : Rhode Island Hospital Updated
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Providence : Women and Infants Hospital
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
South Carolina
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Anderson : AnMed Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Charleston :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Charleston :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Charleston : The Breast Place
NBRST: Prospective Neo-adjuvant REGISTRY Trial
View More »
Charleston : Cancer Specialists of Charleston
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Charleston : Roper Hosp & Med Asso (Care Alliance Health)
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Charleston : Charleston Hematology Oncology Association PA
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Charleston : Hollings Cancer Center at Medical University of South Carolina
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Charleston :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Charleston : Site Reference ID/Investigator# 60752
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Columbia :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Columbia :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Easley : Cancer Centers of the Carolinas - Easley
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Greenville : Cancer Center of the Carolinas
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Greenville : Cancer Centers of the Carolinas Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Greenville : Greenville Hospital Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Cancer Centers of the Carolinas - Grove Commons
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Cancer Centers of the Carolinas - Faris Road
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Bon Secours St. Francis Health System
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : CCOP - Greenville
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Cancer Centers of the Carolinas - Eastside
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Cancer Centers of the Carolinas Dept. of CC of the Carolinas
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Greenwood : Self Regional Cancer Center at Self Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greer : Cancer Centers of the Carolinas - Greer Radiation Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greer : Cancer Centers of the Carolinas - Greer Medical Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Murrells Inlet : Coastal Carolina Breast Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Seneca : Cancer Centers of the Carolinas - Seneca
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spartanburg : Spartanburg Regional Healthcare System
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Spartanburg : CCOP - Upstate Carolina
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spartanburg : Cancer Centers of the Carolinas - Spartanburg
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spartanburg : Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sumter : Santee Hematology/Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
South Dakota
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Sioux Falls : Avera Research Institute Avera SC
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Sioux Falls :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Sioux Falls : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Sioux Falls : Avera Research Institute Updated
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
View More »
Sioux Falls : Sanford Cancer Center at Sanford USD Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Watertown : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Tennessee
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Bristol :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Bristol : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Bristol : Research Site Updated
Video Impact on Neulasta Education
Chattanooga :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
View More »
Chattanooga :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Chattanooga : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Chattanooga :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Chattanooga : Chattanooga Oncology Hematology Associates
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Cookeville : Cookeville Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Germantown : The Jones Clinic
Adenoviral Vector Monotherapy or Combination With Chemotherapy Study in Subjects With Recurrent/Metastatic Breast Cancer and Accessible/Visible Lesions
Germantown : Sandoz Investigational Site
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Kingsport :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Knoxville : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Knoxville :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Knoxville : Tennesee Cancer Specialists
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Knoxville : Tennessee Cancer Specialists Center for Biomedical Research
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Memphis : The West Clinic Dept. of the West Clinic
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Memphis : The West Clinic Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Memphis : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Memphis :
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Memphis :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Memphis : Site Reference ID/Investigator# 65487
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Nashville :
A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer
Nashville : Vanderbilt University Medical Center Vanderbilt - Thompson Ln Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Nashville :
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Nashville : Vanderbilt-Ingram Cancer Center Updated
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Nashville : Sarah Cannon Research Institute
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor
Nashville :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Nashville :
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Nashville :
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols
Nashville :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Nashville : Vanderbilt University Medical Center
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Nashville : Nashville Breast Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Nashville : Tennessee Oncology
Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
Nashville : Vanderbilt University Medical Center Vanderbilt - Thompson Ln
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Nashville :
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Nashville : Sarah Cannon Research Institute
Safety Study of MGAH22 in HER2-positive Carcinomas
Nashville : Vanderbilt-Ingram Cancer Center
Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Nashville :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Nashville :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Nashville : Sarah Cannon Research Institute
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
Nashville : Sarah Cannon Research Institute
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Nashville : Tennessee Oncology, PLLC
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Texas
Abilene :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Amarillo : Texas Oncology - Amarillo
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Amarillo : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Amarillo : Texas Tech University
NBRST: Prospective Neo-adjuvant REGISTRY Trial
View More »
Amarillo : Harrington Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Austin :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Austin : Texas Oncology-Austin Central
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Bedford :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Bedford : Texas Oncology - Bedford
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Bryan :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Corpus Christi : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Dallas : Texas Oncology, P.A. Texas Oncology - Fort Worth (3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Dallas : Texas Oncology, P.A. Texas Oncology - Sammons
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Dallas : Texas Oncology, P.A. Central Austin Cancer Center
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Dallas : US Oncology Central Monitoring
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Dallas : Baylor College of Medicine SC Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Dallas : Pfizer Investigational Site Updated
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
Dallas :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Dallas : Texas Oncology, P.A. Central Austin CancerCenter(2) Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Dallas : University of Texas Southwestern Medical Center Harry Hines Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Dallas : Baylor College of Medicine Baylor Texas Oncology Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Dallas : Texas Oncology - Baylor Charles A Sammons Cancer Center
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Dallas : Texas Oncology - Medical City
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Dallas : Texas Oncology - Dallas
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Dallas : Mary Crowley Cancer Research Center
Adenoviral Vector Monotherapy or Combination With Chemotherapy Study in Subjects With Recurrent/Metastatic Breast Cancer and Accessible/Visible Lesions
Dallas : UT Southwestern Medical Center / Simmons Comprehensive Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Dallas : Dallas Surgical Group
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Dallas : Texas Health
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Dallas : Texas Oncology, P.A. Midtown
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Dallas : Texas Oncology, P.A. TX Onc - Med City Dallas
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Dallas : Texas Oncology, P.A. TX Onc - Southwest
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Dallas : Texas Oncology, P.A. TX Onc - Bedford
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Dallas :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Dallas : Site Reference ID/Investigator# 60745
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Dallas : UT Southwestern
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Edinburg : McAllen Oncology
NBRST: Prospective Neo-adjuvant REGISTRY Trial
El Paso : Texas Oncology -El Paso
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Fort Hood : Carl R. Darnall Army Medical Center
Vaccine Therapy in Treating Patients With Breast Cancer
Fort Sam Houston : Brooke Army Medical Center (now SAMMC) Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Fort Sam Houston : Brooke Army Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Sam Houston : San Antonio Army Medical Center
Vaccine Therapy in Treating Patients With Breast Cancer
Fort Worth :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Fort Worth :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Fort Worth :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Galveston : University of Texas Medical Branch
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Garland :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Garland : Texas Oncology - Garland
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Houston : TOPS
A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population
Houston : Synta Pharmaceutical Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Houston : MD Anderson Cancer Center/University of Texas UT MD
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Houston :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Houston :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Houston :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Houston : Texas Oncology - Memorial City
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Houston : Baylor College of Medicine
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Houston : U T M D Anderson Cancer Center
Dose-escalation Study of Oral CX-4945
Houston : Baylor College of Medicine Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Houston : University of Texas MD Anderson Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Houston : Baylor College of Medicine Lester and Sue Smith Breast Center
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Houston : UT MD Anderson Cancer Center
Genomic Testing for Primary Breast Cancer
Houston : UT MD Anderson Cancer Center
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Houston : East Houston General Surgery
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Houston : The Methodist Hospital Cancer Center Updated
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Houston : UT MD Andreson Cancer Center
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
Houston : UT MD Anderson Cancer Center
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Houston : MD Anderson Cancer Center
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Houston : Oncology Consultants Oncology Consultants
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Houston : The Methodist Hospital Research Institute
Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients
Houston : UT MD Andreson Cancer Center
Preventing Sexual Dysfunction With Aromatase Inhibitors
Houston : Veterans Affairs Medical Center - Houston
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : Baylor University Medical Center - Houston
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : M. D. Anderson Cancer Center at University of Texas
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : Ben Taub General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Houston : MD Anderson Cancer Center
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
Houston : Site Reference ID/Investigator# 60742
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Houston : Memorial Hermann Hospital
The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer
Houston : UT MD Anderson Cancer Center
TKI258 for Metastatic Inflammatory Breast Cancer Patients
Houston : UT MD Anderson Cancer Center
TPI 287 in Breast Cancer Metastatic to the Brain
Houston : University of Texas MD Anderson Cancer Center
Vaccine Therapy in Treating Patients With Breast Cancer
Lewisville : Texas Oncology - Lewisville
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Lubbock : Joe Arrington Cancer Research & Treatment Center Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
McAllen : Texas Oncology - McAllen
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
New Braunfels :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Plano :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Plano : Texas Oncology Plano East
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Plano : Plano Cancer Institute
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
San Antonio :
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
San Antonio : Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5) Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
San Antonio :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
San Antonio : Cancer Care Centers of South Texas
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
San Antonio :
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols
San Antonio : Cancer Centers of South Texas
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
San Antonio : Clinical Trials of Texas, Inc Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
San Antonio : Radiation Oncology of San Antonio
NBRST: Prospective Neo-adjuvant REGISTRY Trial
San Antonio : Kathryn A. Wagner Private Practice
NBRST: Prospective Neo-adjuvant REGISTRY Trial
San Antonio : Cancer Therapy & Research Center / UT Health Science Center Institute for Drug Development
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
San Antonio : University of Texas Health Science Center at San Antonio
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
San Antonio : University Hospital - San Antonio
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
San Antonio : Cancer Therapy and Research Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
San Antonio : Veterans Affairs Medical Center - San Antonio (Murphy)
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
San Antonio : Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
San Antonio : Cancer Therapy and Research Center
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
San Antonio : STOH Clinical Research
Vaccine Therapy in Treating Patients With Breast Cancer
Temple :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Temple : CCOP - Scott and White Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
The Woodlands :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Tyler : Texas Oncology - Tyler
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Tyler :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Tyler :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Utah
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
American Fork : American Fork Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cedar City : Sandra L. Maxwell Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Logan : Logan Regional Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Murray : Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Ogden :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Ogden :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Ogden :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Ogden : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Ogden : Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Provo : Utah Valley Regional Medical Center - Provo
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Salt Lake City : Utah Cancer Specialists Dept.of Utah Cancer Spec. (3)
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Salt Lake City : Huntsman Cancer Institute at University of Utah
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salt Lake City : Utah Cancer Specialists at UCS Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salt Lake City : LDS Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salt Lake City : Site Reference ID/Investigator# 62722
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
St. George : Dixie Regional Medical Center - East Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Vermont
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Virginia
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Charlottesville : University of Virginia Updated
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Charlottesville : University of Virginia
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
Charlottesville : Virginia Breast Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Chesapeake : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
View More »
Chesapeake :
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Danville : Research Site Updated
Video Impact on Neulasta Education
Fairfax : Virginia Cancer Specialists Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Fairfax : Fairfax Northern Virginia Hematology Oncology Dept.ofFairfax SC
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Fredericksburg :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Fredericksburg : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Fredericksburg : Fredericksburg Oncology, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Harrisonburg : Rockingham Memorial Hospital
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Lorton : Surgical Specialists of Northern Virginia
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Lynchburg : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Lynchburg :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Lynchburg : Lynchburg Hematology Oncology Clinic
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Midlothian : Bon Secours Virginia Breast Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Newport News :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Newport News : Sandoz Investigational Site
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Norfolk : Virginia Oncology Associates
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Reston : Medical Oncology & Hematology Associates of Northern VA Med Onc Hem Northern VA Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Richmond :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Richmond : Virginia Commonwealth University Massey Cancer Center
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Richmond : Virginia Commonwealth University
Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB
Richmond :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Richmond : Virginia Cancer Institute
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Roanoke : Blue Ridge Cancer Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Roanoke : Oncology Hematology Associates of Southeast Virginia Salem VA Branch
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Winchester :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Winchester :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Washington
Tacoma : MultiCare Health System
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
Tacoma : MultiCare Health System
Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Anacortes : Island Hospital Cancer Care Center at Island Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bellingham : St. Joseph Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bremerton : Olympic Hematology and Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Burien : Highline Medical Center Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Centralia : Providence Centralia Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Edmonds :
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Everett : Providence Regional Cancer Partnership
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Federal Way : St. Francis Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Issaquah : Swedish Medical Center - Issaquah Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kennewick : Columbia Basin Hematology Columbia Basin
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Kennewick : Columbia Basin Hematology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kirkland : Cascade Cancer Center at Evergreen Hospital Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mount Vernon : Skagit Valley Hospital Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Olympia : Providence St. Peter Hospital Regional Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Poulsbo : Harrison Poulsbo Hematology and Onocology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Puyallup : Good Samaritan Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Seattle : Puget Sound Cancer Center
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Seattle : Swedish Cancer Institute Research Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Seattle : Swedish Cancer Institute
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Seattle : CCOP - Virginia Mason Research Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Group Health Central Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Harborview Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Fred Hutchinson Cancer Research Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Virginia Mason Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Pacific Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Polyclinic First Hill
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Minor and James Medical, PLLC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : University Cancer Center at University of Washington Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sedro-Woolley : North Puget Oncology at United General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spokane : Rockwood Clinic Rockwood Clinic, PS
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Spokane : Rockwood Clinic
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Spokane : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Spokane : Cancer Care Northwest CC Northwest- Spokane South
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Spokane : Cancer Care Northwest - Spokane South
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spokane : Evergreen Hematology and Oncology, PS
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : Multicare Health System-Research Institute Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Tacoma : Allenmore Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : St. Clare Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : MultiCare Regional Cancer Center at Tacoma General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : CCOP - Northwest
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : Franciscan Cancer Center at St. Joseph Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : Madigan Army Medical Center - Tacoma
Vaccine Therapy in Treating Patients With Breast Cancer
Vancouver : Legacy Salmon Creek Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Vancouver : Southwest Washington Medical Center Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Walla Walla :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Wenatchee : Wenatchee Valley Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wenatchee : Wenatchee Valley Medical Center Wenatchee Valley
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Yakima : Yakima Valley Memorial Hospital
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
BIG411-Ph3 Chemo + Herceptin + Placebo / Pertuzumab as Adjuvant Therapy for Operable HER-2 + Breast CA
Morgantown : West Virginia University - Clinical Trials Research Unit
CIRB) NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Morgantown : West Virginia University - Clinical Trials Research Unit
ECOG5508 - Randomized Phase III Study of Maintenance Therapy with Bevacizumab,Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Morgantown : West Virginia University - Clinical Trials Research Unit
GO25632 A Phase III, Randomized, Double-Blind,Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Bevacizumab
Morgantown : West Virginia University - Clinical Trials Research Unit
NSABP-B47 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Morgantown : West Virginia University - Clinical Trials Research Unit
NSABP-B49 - A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Morgantown : West Virginia University - Clinical Trials Research Unit
NSABP-FB7 A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens
Morgantown : West Virginia University - Clinical Trials Research Unit
NSABP-FB9 A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens
Morgantown : West Virginia University - Clinical Trials Research Unit
RTOG-1005 - A Phase III Trial of Accelerated Whole Breast Irradiation
View More »
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Morgantown :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Morgantown :
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Morgantown : Mary Babb Randolph Cancer Center at West Virginia University Hospitals Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Morgantown : West Virginia University Hospitals Inc.
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Wisconsin
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Green Bay :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Green Bay : Cancer TEAM Bellin Health Belin Health
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Green Bay : Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Green Bay : St. Vincent Hospital Regional Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
View More »
Green Bay : St. Mary's Hospital Medical Center - Green Bay
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Green Bay : Green Bay Oncology, Limited at St. Mary's Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Janesville : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
La Crosse : Gundersen Lutheran Center for Cancer and Blood
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Madison : University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 2 Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Madison : University of Wisconsin
CO11109: A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Madison : University of Wisconsin Carbone Cancer Center
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
Madison : Dean Health System Dean Hematology Oncology
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Manitowoc : Holy Family Memorial Medical Center Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Marshfield :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Milwaukee : Medical College of Wisconsin Department of Surgery Froedtert Hospital and Cancer Center Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Milwaukee : Columbia St. Marys Cancer Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Oconto Falls : Green Bay Oncology, Limited - Oconto Falls
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Racine : Research Site
NOLAN: Naproxen or Loratadine and Neulasta
Sheboygan : St. Nicholas Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sturgeon Bay : Green Bay Oncology, Limited - Sturgeon Bay
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Waukesha : Waukesha Memorial Hospital
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Wauwatosa : Wheaton Franciscan Healthcare
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Wyoming
Additional Locations :
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Casper : Rocky Mountain Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Albania
Tirana :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Algeria
Algiers :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Argentina
Acevedo : Unidad de Investigación FP Clinical Pharma en Centro Medico Integral Fitz Roy
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Buenos Aires : Novartis Investigative Site
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Buenos Aires :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Buenos Aires :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Buenos Aires :
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
View More »
Buenos Aires : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Buenos Aires : Hospital Interzonal General De Agudos EvaPeron
Perioperative Use of Desmopressin (DDAVP) in Breast Cancer
Buenos Aires : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Buenos Aires : Novartis Investigative Site
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Caba :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Caba :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Cordoba : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Cordoba : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Cordoba : Novartis Investigative Site
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
La Plata :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
La Plata : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
La Rioja :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Mendoza : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Quilmes : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Rio Negro : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Rio Negro : Novartis Investigative Site
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Rosario :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Rosario : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Rosario :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Rosario Santa Fe : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
San Miguel de Tucuman :
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
San Miguel de Tucuman :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Santa Fe :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Tucuman : Novartis Investigative Site
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Tucuman : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Tucuman : Novartis Investigative Site
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Zarate :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Australia
Adelaide :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Adelaide :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Adelaide : Site Reference ID/Investigator# 63280
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Auchenflower :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Bedford Park :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
View More »
Bendigo : Research Site Updated
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Camperdown :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Canberra :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Chermside :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Clayton : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
East Bentleigh :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
East Melbourne : Site Reference ID/Investigator# 63272
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Footscray :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Footscray :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Frankston :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Frankston :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Geelong :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Geelong : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Heidelberg :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Hobart :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Hobart : Site Reference ID/Investigator# 63279
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Kogarah :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Kogarah :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Lismore :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Malvern :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Melbourne :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Melbourne :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Melbourne : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Milton :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Milton :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Milton :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Milton : Site Reference ID/Investigator# 63276
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Murdoch : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
North Sydney :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Parkville :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Parkville : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Parkville :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Parkville : Site Reference ID/Investigator# 63278
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Perth : Novartis Investigative Site Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Perth :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Perth :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Perth : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Perth : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Perth : Site Reference ID/Investigator# 65262
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Randwick : Site Reference ID/Investigator# 63271
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Shepparton : Research Site Updated
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Sydney :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Sydney :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Sydney : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Sydney : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Sydney : St George Hospital
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
Sydney : St George Private Hospital
Use of Hair to Diagnose Breast Cancer
Sydney : The Mater Hospital
Use of Hair to Diagnose Breast Cancer
Sydney : Penrith Imaging
Use of Hair to Diagnose the Presence of Breast Cancer
Sydney : Bankstown Diagnostic Imaging Centre
Use of Hair to Diagnose the Presence of Breast Cancer
Sydney : Campbelltown Ultrascan Radiology
Use of Hair to Diagnose the Presence of Breast Cancer
Sydney : Liverpool Ultrascan Radiology
Use of Hair to Diagnose the Presence of Breast Cancer
Sydney : Diagnostic Imaging Centre, St George Private Hospital
Use of Hair to Diagnose the Presence of Breast Cancer
Tweed Heads : Research Site Updated
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Wahroonga :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Waratah :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Westmead : Site Reference ID/Investigator# 63273
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Wodonga :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Wollongong : Site Reference ID/Investigator# 63274
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Woodville :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Woolloongabba :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Austria
Baden : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Bludesch :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Braunau : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Dornbirn : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Eggenburg : Research Site Updated
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
View More »
Feldkirch : State Hospital Feldkirch, Coop. Group
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Feldkirch :
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Feldkirch : State Hospital Feldkirch
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Feldkirch : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Güssing : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Gmunden : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Graz : Medical University of Graz-Oncology; Coop. Group
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Graz : Novartis Investigative Site
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Graz :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Graz :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Graz : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Graz : Medical University Graz, Oncology
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Graz : Gynaegological Medical University Graz
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Graz : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Guessing : Hospital Guessing
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Hall in Tirol : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Innsbruck : Gynaegological Medical University Innsbruck
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Innsbruck : Novartis Investigative Site
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Innsbruck :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Innsbruck : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : Medical University of Innsbruck
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Innsbruck : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Klagenfurt : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Krems :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Krems an der Donau : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Kufstein : District Hospital Kufstein
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Kufstein : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Leoben : State Hospital Leoben
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Leoben : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Lienz : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Linz : Hospital BHS Linz, Coop. Study Group
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Linz : AKH Linz
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Linz : Novartis Investigative Site
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Linz :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Linz : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Linz : General Hospital Linz
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Linz : Hospital Elisabethinen Linz
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Linz : Hospital BHS Linz, Coop. Study Group
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Linz : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Oberpullendorf : Hospital Oberpullendorf
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Oberpullendorf : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Rankweil :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Ried : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Rottenmann : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Salzburg : Paracelsus Medical University Salzburg-Oncology, Coop. Group
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Salzburg : Novartis Investigative Site
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Salzburg :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Salzburg :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Salzburg :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Salzburg : Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum
Exercise Training in Postmenopausal Patients With Breast Cancer
Salzburg : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Salzburg : Paracelsus Medical University Salzburg-Oncology, Coop. Group
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Salzburg : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Salzburg : Novartis Investigative Site
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Schärding : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
St Poelten : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
St Poelten : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
St Veit An Der Glan :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
St Veit an der Glan : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
St. Poelten : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
St. Veit a. d. Glan : Ordination Dr. Wette
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Steyr : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Vöcklabruck : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Vienna : Medical University Vienna, General Hospital
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Vienna : Med. Univ. Vienna; General Hospital Vienna
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Vienna : State Hospital Vienna-Hietzing
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Vienna : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Vienna : Medical University of Vienna-General Hospital Vienna
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Vienna : Medical University of Vienna
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Villach :
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Villach : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Vocklabruck : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Weiz : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Wels : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wels : Klinikum Wels-Grieskirchen GmbH
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Wels : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Wien : Novartis Investigative Site
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Wien :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Wien :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Wien : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Wien : Research Site Updated
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Wien : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Wien : Novartis Investigative Site
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Wiener Neustadt : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Wolfsberg : Research Site
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Belgium
Aalst : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Anderlecht :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Antwerp : Universitair Ziekenhuis Antwerpen
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Bonheiden : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasschaat :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
View More »
Brasschaat : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Brugge : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brussel :
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Brussel : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Brussels : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Brussels : Jules Bordet Institute
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Brussels : Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
Brussels : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Bruxelles :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Bruxelles :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Bruxelles :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Bruxelles : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Bruxelles : GSK Investigational Site
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
Bruxelles : Université
Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon
Bruxelles : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Bruxelles :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Charleroi : Synta Pharmaceutical Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Charleroi :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Charleroi :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Charleroi : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Charleroi : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Edegem :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Edegem :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Edegem : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Edegem :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Eupen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gent :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Gent : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Gent :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Gent : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Gilly : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Haine Saint Paul : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Haine-saint-paul :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Hasselt :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Jette : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Kortrijk :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Leuven :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Leuven : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Leuven : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Leuven : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Leuven : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Leuven : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Leuven :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Leuven : Novartis Investigative Site
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Liege : Novartis Investigative Site
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
Liege :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Liege : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Liege :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Liege : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Liege : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Liege :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Liège :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Liège : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Liège : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Liège : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Mechelen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Namur :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Namur :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Namur :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Namur : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Namur : GSK Investigational Site
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Namur : GSK Investigational Site
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
Namur : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Oostende : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ottignies : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Sint-Niklaas : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
St. Niklaas : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Verviers : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Verviers : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wilrijk : Synta Pharmaceuticals Investigative Site
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer
Wilrijk :
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Wilrijk : Novartis Investigative Site Updated
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Wilrijk : Novartis Investigative Site Updated
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Wilrijk :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Wilrijk : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Wilrijk : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Wilrijk : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Wilrijk : Novartis Investigative Site
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Yvoir : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Bosnia and Herzegovina
Banja Luka :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Sarajevo :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Brazil
Cachoeiro Do Itapemirim :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Goiania :
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Goiânia/Go : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Ijuí : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Itajai :
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
View More »
Jau : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Porto Alegre :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Porto Alegre :
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Porto Alegre : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Ribeirão Preto/Sp : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Santo Andre : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Sao Jose Do Rio Preto : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Sao Paulo :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Sao Paulo :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Sao Paulo : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Sao Paulo :
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
Sao Paulo :
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
São Paulo- Sp :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
São Paulol : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Bulgaria
Plovdiv :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Plovdiv : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Plovdiv : Central Onco Hospital Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Sofia :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Sofia : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
View More »
Sofia :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Sofia :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Sofia : Tsaritsa Yoanna - ISUL Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Sofia : Serdika Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Stara Zagora : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Tarnovo : Veliko Tarnovo Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Varna : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Varna :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Varna : Sveta Marina Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Canada
Barrie :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Calgary : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Cambridge : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Edmonton :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Edmonton :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
View More »
Edmonton : Cross Cancer Institute Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Edmonton : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Greenfield Park :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Greenfield Park : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Greenfield Park : Hospital Charles LeMorne Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Halifax :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Halifax : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Hamilton :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Kelowna :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Kelowna : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Kelowna : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Kingston :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Laval : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
London :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
London : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Mississauga :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Moncton :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Moncton : Research Site Updated
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Montreal :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Montreal :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Montreal :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Montreal : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Montreal : Montreal General Hospital Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Montreal : Centre Hospitalier de l'Universite de Montreal Updated
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Montreal : Jewish General Hospital
Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis
Montreal : Jewish General Hospital
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Montreal : University of Montreal Hospital Group
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Montreal : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Montreal : Updated
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Montreal : Research Site Updated
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Montreal :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Montreal : Site Reference ID/Investigator# 69893
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Montreal : Site Reference ID/Investigator# 67862
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Newmarket :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Newmarket :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Newmarket : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Oshawa :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Oshawa :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Oshawa : GSK Investigational Site
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Ottawa : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Quebec : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Quebec City : Updated
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Quebec City : Site Reference ID/Investigator# 68902
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Red Deer : CAMIS - Central Alberta Medical Imaging Services
Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System
Regina :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Regina : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Saint John :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Saskatoon :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Sault Ste. Marie : Research Site Updated
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Sherbrooke : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
St Catharines : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
St. Catharines :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
St. John's :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Sudbury :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Sudbury : Health Sciences North Cancer Centre Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Surrey :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Toronto : Novartis Investigative Site
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Toronto : Sunnybrook Health Sciences Centre
A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer
Toronto :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Toronto :
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Toronto :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Toronto :
A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Toronto : University Health Network (UNH) - Princess Margaret Hospital
Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System
Toronto : GSK Investigational Site
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Toronto : Odette Cancer Centre/Sunnybrook Health Sciences Centre
Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab
Toronto : St. Michael's Hospital
Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab
Toronto : Sunnybrook Research Institute Updated
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Toronto : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Toronto : Familial Breast Cancer Research Unit, Women's College Research Institute
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers
Toronto : Site Reference ID/Investigator# 77373
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Vancouver :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Vancouver : Novartis Investigative Site
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Victoria :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Windsor :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Winnipeg :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Chile
Antofagasta :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Paraiso : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Santiago :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Santiago :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Santiago :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
View More »
Temuco :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Temuco : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Temuco :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Valparaiso :
A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
Valparaiso :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Vina del Mar :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
China
Beijing :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Beijing : Pfizer Investigational Site
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Beijing : Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
Beijing : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Beijing : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
View More »
Beijing : Updated
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Beijing : Peking University School of Oncology/Beijing Cancer Hospital
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Changchun : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Changsha : Pfizer Investigational Site
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Changsha : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Chendu : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Chengdu :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Chengdu : Pfizer Investigational Site
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Chengdu : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Chongqing : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Dalian : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Fuzhou : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Guangzhou : Pfizer Investigational Site
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Guangzhou : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Guangzhou : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Guiyang : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Hangzhou : Pfizer Investigational Site
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Hangzhou : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Hangzhou : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Harbin :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Harbin : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Harbin : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Hefei : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Huhehaote : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Jinan : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Kunming : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Kunshan : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Nanjing : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Nanjing : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Nanning : Reseacrh Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Nanning : Updated
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Nantong : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Qingdao : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Shanghai :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Shanghai : Pfizer Investigational Site
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Shanghai : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Shanghai : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Shanghai : Cancer Hospital Affiliated to Fudan University
Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer
Shanghai : Updated
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Shanghai : Fudan University Cancer Hospital
Study of Arimidex and Radiotherapy Sequencing
Shenyang : Updated
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Shijiazhuang : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Suzhou :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Taiyuan : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Tangshan : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Tianjin : Pfizer Investigational Site
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Tianjin : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Tianjin : Research Site
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer
Tianjin : Updated
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Weifang : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Wuhan :
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Wuhan : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Xi`an : Xijing Hospital ， Fourth Military Medical University
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
Xi'an : Updated
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Yuezhou : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Zhoushan : Research Site
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Colombia
